## ZBH: Zimmer Biomet Holdings, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (46% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($86.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Collagen Meniscus Implant Market Forecast: Unveiling High-Growth Business Opportunities for the New Year | Zimmer Biomet Holdings, Inc., RTI Surgical Holdings, Inc.**
- Source: openPR.com | 20251229T070909 | Somewhat-Bullish | Relevance: 91%
- The Collagen Meniscus Implant Market is projected for strong growth from 2025 to 2032 due to rising demand, expanding applications, and technological advancements. A new report by Coherent Market Insights details market size, revenue trends, key growth factors, and competitive landscapes, offering actionable insights for data-driven decisions. Leading companies like Zimmer Biomet Holdings Inc. and RTI Surgical Holdings Inc. are highlighted in this comprehensive analysis.

**2. Stryker stock slips today as year-end trading turns cautious â€” dividend date and new COO in focus**
- Source: ts2.tech | 20251230T041113 | Somewhat-Bearish | Relevance: 63%
- Stryker (SYK) shares closed down 0.5% in cautious year-end trading, with investors focused on a December 31st dividend record date and a January 1st leadership change as Spencer Stiles becomes President and COO. The stock is holding near a $350 support level, and the company has declared a quarterly dividend of $0.88 per share. The broader market also saw a pullback in the final week of 2025.

**3. Key sale, acquisition helped Solventum turn around in 2025**
- Source: Star Tribune | 20251230T160523 | Neutral | Relevance: 62%
- Solventum, a 3M spinoff, overcame initial investor unrest in 2025 by selling its purification and filtration business for $4 billion and acquiring Acera Surgical for $850 million. These strategic moves allowed the company to pay down debt, streamline its portfolio, and attract renewed investor confidence, leading to a significant turnaround in its financial performance and stock price. CEO Bryan Hanson's focus on efficiency and a decentralized structure has positioned the company for positive momentum in 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $100 | $117 | -15% |
| 2025-12-11 | Citigroup | $94 | $98 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (+0.2%)
- Dodge & Cox Inc.: 11.7% (+5.1%)
- Blackrock Inc.: 8.1% (+0.2%)
- Price (T.Rowe) Assoc: 7.6% (+1.9%)
- State Street Corpora: 4.4% (-1.3%)

### Key Risks

1. Long-term trend broken: trading 7.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- M&A activity or partnership announcements may unlock value.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Forward P/E 10.6x stretched relative to 4% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $17.8B |
| Beta | 0.61 |
| 52W Range | $85.33 - $114.44 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 10.6 |
| Current P/E | 11.0 |
| YoY Growth | 4.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.6% to -0.9% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.5%) - potential reversal signal. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 42. Volume at 46% of 20MA suggests lack of conviction. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.86% (CS: 35) | Neutral |
| RSI_14 | 42.0 | Neutral |
| MACD Histogram | 0.02 | Bullish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.960x | Below |
| vs SMA200 | 0.921x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $89.90
- **Stop Loss:** $86.28 (4.0% risk)
- **Target:** $97.14 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 397
- **Position Value:** $35,690.30
- **Portfolio %:** 35.69%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-05 (Est: $2.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.87 | $1.90 | +1.8% |
| 2025Q2 | $1.98 | $2.07 | +4.8% |
| 2025Q1 | $1.77 | $1.81 | +2.3% |
| 2024Q4 | $2.29 | $2.31 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*